-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Sodium valproate
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1069-66-5.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 1069-66-5 |
| Description | Valproic acid is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. |
Product Information
| Synonyms | Valproic Acid, Convulex, Depakote, Epilim, Stavzor, Vilapro |
| IUPAC Name | sodium;2-propylpentanoate |
| Molecular Weight | 166.19 |
| Molecular Formula | C8H15NaO2 |
| Canonical SMILES | CCCC(CCC)C(=O)[O-].[Na+] |
| InChI | InChI=1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1 |
| InChIKey | AEQFSUDEHCCHBT-UHFFFAOYSA-M |
| Purity | >98% |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White crystalline powder |
| Application | Anticonvulsants |
| Storage | 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture) |
| In Vitro | Valproic acid (VPA) (0-15 mM; 24 and 72 h) inhibits Hela cell growth in a dose- and time- dependent manner. Valproic acid (10 mM; 24 h) significantly attenuates the activities of total, cytosol and nuclear HDACs. Valproic acid (0-15 mM; 24 h) induces a G1 phase arrest at 1-3 mM and a G2/M phase arrest at 10 mM, and increases the percentage of sub-G1 cells in HeLa cells. Valproic acid also induces necrosis, Apoptosis and Lactate dehydrogenase (LDH) release. Valproic acid (0-20 mM; 24 h) activates Tcf/Lef-dependent transcription and synergizes with lithium. Valproic acid (0-5 mM; 0-18 h) increases β-catenin levels in Neuro2A cells. Valproic acid (0-2 mM; 0-24 h) stimulates phosphorylation of AMPK and ACC in hepatocytes. Valproic acid (0-10 mM; 2 days) induces Notch1 signaling and morphologic differentiation, suppresses production of NE tumor markers in SCLC cells. |
| In Vivo | Valproic acid (VPA) (500 mg/kg; i.p.; daily for 12 days) inhibits tumor angiogenesis in mice transplanted with Kasumi-1 cells. Valproic acid (350 mg/kg; i.p.; once) enhances social behavior in rats. Valproic acid (0.26% (w/v); p.o. via drinking water; 14 days) decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice without hepatotoxicity. |
| PSA | 60.36000 |
| Target | HDAC; Autophagy; Mitophagy; HIV; Notch; Apoptosis; Endogenous Metabolite |
